Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study

Fluperlapine (NB-106-689) was tested on 26 schizophrenic patients in an open and crossover study. In addition to its good antipsychotic effect, it also alleviated the apathic and depressive syndromes. Six patients who had shown only slight or no improvement after 4 weeks of haloperidol therapy responded positively to fluperlapine. The alleviation of the anergic syndrome was especially impressive. The therapeutic response of the depressive-apathic syndromes could represent an important extension of pharmacotherapy for schizophrenia. The virtual lack of extrapyramidal motor side effects with fluperlapine supports an intensification of the search for Other nonclassic dibenzo-epine neuroleptics.